Previous 10 | Next 10 |
NEW HAVEN, Conn., May 03, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience ...
The Campaign, launching during Mental Health Awareness Month, aims to educate healthcare providers on the various signs, symptoms, and levels of severity associated with agitation Interactive website offers healthcare providers educational resources and guidance on methods of ma...
NEW HAVEN, Conn., April 26, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today...
Shares of BioXcel Therapeutics (NASDAQ: BTAI) are trading lower on Thursday after the company reported somewhat disappointing data from a clinical trial for one of its leading pipeline candidates, BXCL501, on Wednesday evening. The biotech's stock was down by 13.3% as of 2:31 p.m. E...
Gainers: AeroCentury (ACY) +235%.Liberty TripAdvisor (LTRPB) +106%.Uxin (UXIN) +53%.Universe Pharmaceuticals (UPC) +36%.Applied Molecular Transport (AMTI) +31%.Euro Tech Holdings (CLWT) +26%.PLBY Group (PLBY) +25%.Nuvve (NVVE) +24%.Moxian (MOXC) +18%.Sonoma Pharmaceuticals (SNOA) +1...
Gainers: Universe Pharmaceuticals UPC +50%, Applied Molecular Transport AMTI +26%, Sonoma Pharmaceuticals (SNOA) +17%, United Therapeutics UTHR +16%, PAVmed (PAVM) +12%.Losers: AzurRx BioPharma (AZRX) -28%, BioXcel Therapeutics (BTAI) -14%,...
BioXcel Therapeutics (BTAI) shares drop nearly 10% during after market trading after posting topline results from its Phase 1b/2 proof-of-concept RELEASE study of BXCL501, the company’s proprietary, orally dissolving thin film formulation of dexmedetomidine, for the trea...
Primary safety endpoint achieved in first study of BXCL501 dosed twice-daily over seven days RELEASE results demonstrated numerically improved retention rates in multiple BXCL501 dose cohorts Data from multiple dosing regimen in RELEASE supports investigation across...
Intec Pharma Ltd (NTEC) +142% on announcing merger agreement with Decoy Biosystems.Check-Cap Ltd. (CHEK) +113% after receiving FDA IDE approval for pivotal study of C-Scan®.Acer Therapeutics (ACER) +67%.Shaw Communications (SJR) +55% as Rogers to acquire the company in C$2...
The FDA has granted Breakthrough Therapy designation to BioXcel Therapeutics' (BTAI) BXCL501, an orally dissolving thin film formulation of dexmedetomidine for the acute treatment of agitation associated with dementia.Breakthrough Therapy status provides for more intensive guidance from the F...
News, Short Squeeze, Breakout and More Instantly...
BioXcel Therapeutics Inc. Company Name:
BTAI Stock Symbol:
NASDAQ Market:
BioXcel Therapeutics Inc. Website:
Focused market-access strategy generates estimated net revenue of approximately $1.1 million, highest quarterly net revenue since commercial launch Represents 90% increase from the prior quarter and 141% increase from the second quarter of 2023 NEW HAVEN, Conn., July 16, 2024 (GLO...
Study achieved its objective and demonstrated no evidence of tachyphylaxis, tolerance, or withdrawal with 180 mcg dose (highest approved dose) For each episode occurring over seven days, a reduction in agitation was observed and no serious adverse events were reported following treatmen...
NEW HAVEN, Conn., May 28, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that CEO Vimal Mehta, Ph.D., will present at the Jef...